Get started
Author

Dan McDonald

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
2015 · David F. McDermott, Charles G. Drake, et al. · Journal of Clinical Oncology · 437
Increasing parvovirus filter throughput of monoclonal antibodies using ion exchange membrane adsorptive pre‐filtration
2010 · Arick Brown, Charity Bechtel, et al. · Biotechnology and Bioengineering · 38
Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).
2012 · Julie R. Brahmer, Leora Horn, et al. · Journal of Clinical Oncology · 27
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
2016 · Sonja Althammer, Keith Steele, et al. · Journal for ImmunoTherapy of Cancer · 18
PDF
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).
2012 · David F. McDermott, Charles G. Drake, et al. · Journal of Clinical Oncology · 17
Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.
2012 · Suzanne Louise Topalian, Julie R. Brahmer, et al. · Journal of Clinical Oncology · 16
A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.
2013 · Rachel E. Sanborn, William Howard Sharfman, et al. · Journal of Clinical Oncology · 15
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).
2012 · F. Stephen Hodi, Mario Sznol, et al. · Journal of Clinical Oncology · 15
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
2016 · Andreas Lundqvist, Vincent van Hoef, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
2014 · Neil Howard Segal, F. Stephen Hodi, et al. · Journal of Clinical Oncology · 11
Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
2016 · N.H. Segal, J.R. Infante, et al. · Annals of Oncology · 10
PDF
Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody.
2012 · Shruti Agrawal, Yan Feng, et al. · Journal of Clinical Oncology · 9
Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.
2012 · Suzanne Louise Topalian, Julie R. Brahmer, et al. · Journal of Clinical Oncology · 7
Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)
2019 · J.M. Johnson, D.M. Cognetti, et al. · Annals of Oncology · 4
PDF
Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations
2018 · J.J. Luke, R. Edwards, et al. · Annals of Oncology · 2
An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma.
2012 · Charles G. Drake, Mayer N. Fishman, et al. · Journal of Clinical Oncology
Biopharmaceutical companies tackle clinical trial transparency
2006 · Dan McDonald, Steve Zisson · Birkhäuser Basel eBooks
Works count: 17
Citation count: 637
H-index: 10
I10-index: 11
Year
Topic
Type